Furthermore, studies conducted in 2020 suggested that AG induced DNA damage in HER-2 overexpressing breast cancer cells, indicating its potential efficacy against HER-2-positive breast cancer (Lee et al., 2021). Here, ERBB2 is linked to breast cancer.